Litcius/Paper detail

Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials

Per‐Henrik Groop, Paresh Dandona, Moshe Phillip, Pieter Gillard, Steven V. Edelman, Johan Jendle, John Xu, Markus F. Scheerer, Fredrik Thorén, Nayyar Iqbal, Enrico Repetto, Chantal Mathieu

2020The Lancet Diabetes & Endocrinology78 citationsDOI

Topics & Concepts

DapagliflozinPost-hoc analysisAdjunctMedicineType 2 diabetesPost hocDiabetes mellitusInsulinInternal medicineUrologyEndocrinologyLinguisticsPhilosophyDiabetes Treatment and ManagementDiabetes Management and ResearchPancreatic function and diabetes
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials | Litcius